Product Description: T863 is an orally active, selective and potent DGAT1 (acyl-CoA:diacylglycerol acyltransferase 1) inhibitor with an IC50 of 15 nM. T863 has no inhibitory activity against human MGAT3, human DGAT2, or human MGAT2. T863 interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells[1][2].
Applications: Metabolism-sugar/lipid metabolism
Formula: C22H26N4O3
References: [1]Cao J, et al. Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem. 2011 Dec 2;286(48):41838-51./[2]Alan M Birch, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem. 2009 Mar 26;52(6):1558-68.
CAS Number: 701232-20-4
Molecular Weight: 394.47
Compound Purity: 99.97
Research Area: Metabolic Disease
Solubility: DMSO : ≥ 50 mg/mL
Target: Acyltransferase
Deutsch
English
